Imatinib before rectum-sparing surgery for rectal GIST
Treatments studied
Part of Cancer, Digestive system, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This trial tests whether giving imatinib (a drug that targets the C-KIT gene change) before surgery can help shrink the tumor and allow for a less invasive operation that saves your rectum.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a newly diagnosed GIST (a rare tumor) in the rectum, and it is larger than 2 cm
- Your tumor is located low in the rectum, within 5 cm of the anal opening
- Your tumor has a specific gene change called C-KIT
- You are generally healthy enough for treatment (your doctor will check your blood work and overall condition)
- You have not had targeted therapy (like imatinib) for this tumor before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special MRI technique to see how well imatinib is working on your GIST tumor. It may help doctors understand treatment response better and guide your care.
This trial studies whether doing laparoscopic surgery for stomach GISTs (gastrointestinal stromal tumors) works and is safe when the tumor is in a “favorable” versus “unfavorable” location. You might be eligible if your tumor is confirmed as GIST and doctors expect to remove it completely using keyhole surgery.
This trial studies whether taking imatinib before surgery can shrink or control high-risk gastrointestinal stromal tumors (GIST). If you qualify, you would receive imatinib as “neoadjuvant” (before the operation) and then move on to planned surgery.
This trial tests whether combining two oral medications, imatinib and fampridine, before surgery can shrink GIST tumors that have a specific KIT gene mutation. The goal is to improve surgical outcomes and potentially reduce the risk of the tumor coming back.
This study looks at taking imatinib (a targeted anti-cancer pill) for 5 years after your GIST tumor has been fully removed. It is meant to lower the chance that GIST comes back in people considered “high risk.”
This Phase 2 trial studies how to adjust and monitor imatinib (a targeted cancer medicine) based on drug levels in the blood. It may help people with GIST that has certain KIT or PDGFRA mutations but not the PDGFRA D842V type.
Hear when a new Gastrointestinal Stromal Tumor of Rectum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.